used radiomic to evaluate tumor-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy, which offered a novel method for predicting the immune phenotype and inferring clinical results for cancer patients (6). This evidence concerns the gene CD8A and neoplasm.